Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2005 1
2006 1
2007 1
2008 1
2009 2
2010 10
2011 7
2012 13
2013 8
2014 1
2015 5
2016 10
2017 11
2018 14
2019 6
2020 6
2021 7
2022 5
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.
Shanta K, Nakayama K, Hossain MM, Razia S, Ishibashi T, Ishikawa M, Yamashita H, Kanno K, Sato S, Nakayama S, Otsuki Y, Kyo S. Shanta K, et al. Among authors: ishikawa m. Curr Oncol. 2022 Jun 1;29(6):4020-4033. doi: 10.3390/curroncol29060321. Curr Oncol. 2022. PMID: 35735430 Free PMC article.
Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.
Sasamori H, Nakayama K, Razia S, Yamashita H, Ishibashi T, Ishikawa M, Sato S, Nakayama S, Otsuki Y, Fujiwaki R, Ishikawa N, Kyo S. Sasamori H, et al. Among authors: ishikawa m. Curr Oncol. 2022 May 18;29(5):3658-3667. doi: 10.3390/curroncol29050294. Curr Oncol. 2022. PMID: 35621684 Free PMC article.
Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents.
Nonomura Y, Nakayama K, Nakamura K, Razia S, Yamashita H, Ishibashi T, Ishikawa M, Sato S, Nakayama S, Otsuki Y, Kyo S. Nonomura Y, et al. Among authors: ishikawa m. Healthcare (Basel). 2022 Apr 7;10(4):694. doi: 10.3390/healthcare10040694. Healthcare (Basel). 2022. PMID: 35455871 Free PMC article.
104 results